PBYI PUMA BIOTECHNOLOGY, INC.companySEC Filings & Insider Trading Activity 2026
Latest PUMA BIOTECHNOLOGY, INC. (PBYI) SEC EDGAR filings in 2026, including the most recent 10-K annual report filed on February 26, 2026, a 10-Q quarterly report filed on May 7, 2026, an 8-K current report filed on August 6, 2026. SignalX aggregates every new 10-K annual report, 10-Q quarterly report, 8-K current report, and Form 4 insider transaction for PUMA BIOTECHNOLOGY, INC. (PBYI) (SEC CIK 1401667), with AI-powered section-by-section summaries updated daily.
Latest 2026 SEC Filing Dates
Go deeper on PUMA BIOTECHNOLOGY, INC.
Ask AI about PBYI filings. Chat with the 10-K, 10-Q, and 8-K for instant answers on financials, risks, and guidance.
Track institutional money. See which funds are building or cutting PBYI positions, quarter over quarter.
Catch cross-signals. Spot when insider buying, fund accumulation, and activist stakes line up on PBYI.
Recent 8-K FilingsCurrent Reports
AI-powered analysis of PUMA BIOTECHNOLOGY, INC. (PBYI) 8-K current reports disclosing material events.
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing Date | Period | Analysis | SEC |
|---|---|---|---|---|
8-K | Aug 6, 2026 | - | - | - |
8-K | Jun 16, 2026 | - | - | - |
8-K | May 7, 2026 | - | - | |
10-Q | May 7, 2026 | Mar 31, 2026 | - | |
10-K | Feb 26, 2026 | Dec 31, 2025 | - | |
8-K | Feb 26, 2026 | - | Analysis | - |
10-Q | Nov 6, 2025 | Sep 30, 2025 | - | |
10-Q | Aug 7, 2025 | Jun 30, 2025 | - | |
10-Q | May 8, 2025 | Mar 31, 2025 | - | |
10-K | Feb 27, 2025 | Dec 31, 2024 | - | |
SC 13G | Nov 8, 2024 | - | - | |
10-Q | Nov 7, 2024 | Sep 30, 2024 | - | |
SC 13G | Oct 22, 2024 | - | - | |
10-Q | Aug 1, 2024 | Jun 30, 2024 | - | |
10-Q | May 2, 2024 | Mar 31, 2024 | - | |
SC 13G | Mar 29, 2024 | - | - | |
10-K | Feb 29, 2024 | Dec 31, 2023 | - | |
10-Q | Nov 2, 2023 | Sep 30, 2023 | - | |
SC 13G | Sep 1, 2023 | - | - | |
10-Q | Aug 3, 2023 | Jun 30, 2023 | - | |
10-Q | May 4, 2023 | Mar 31, 2023 | - | |
10-K | Mar 2, 2023 | Dec 31, 2022 | - | |
10-Q | Nov 3, 2022 | Sep 30, 2022 | - | |
10-Q | Aug 4, 2022 | Jun 30, 2022 | - | |
SC 13G | Jul 8, 2022 | - | - |
13F Fund Holdings: Quarterly Trend
Latest: Q1 2026Aggregate PBYI share value held by 13F filers tracked by SignalX, by quarter.
- Millennium Management+1.46M (+8793%)
- AQR Capital Management+133.6K (+20%)
- Dimensional Fund Advisors+96.5K (+7%)
- State Street Corp+40.5K (+5%)
- Morgan Stanley+33.0K (+10%)
- Renaissance Technologies LLC181.4K (-9%)
- Two Sigma Investments149.4K (-92%)
- Citadel Advisors LLC147.5K (-83%)
- Goldman Sachs Group124.2K (-16%)
- BlackRock43.6K (-1%)
- Vanguard Group Inc−3.80M
- Invesco Ltd−108.3K
- JPMorgan Chase & Co−21.1K
Source: 13F-HR filings on SEC EDGAR (aggregated from 158 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe.
Frequently Asked Questions
What are the latest PBYI SEC filings in 2026?
PUMA BIOTECHNOLOGY, INC. (PBYI) has filed a 10-K annual report on February 26, 2026, a 10-Q quarterly report on May 7, 2026, an 8-K current report on August 6, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.
When did PBYI file its most recent 10-K annual report?
PUMA BIOTECHNOLOGY, INC. (PBYI) filed its most recent 10-K annual report on February 26, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.
How do I view PBYI 10-Q quarterly reports?
PUMA BIOTECHNOLOGY, INC. (PBYI)'s most recent 10-Q quarterly report was filed on May 7, 2026. SignalX displays every PBYI 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.
What 8-K current reports has PBYI filed recently?
PUMA BIOTECHNOLOGY, INC. (PBYI)'s most recent 8-K was filed on August 6, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.
Where can I find PBYI insider trading activity (Form 4)?
SignalX aggregates every PBYI Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.
How often does PBYI file with the SEC?
PUMA BIOTECHNOLOGY, INC. (PBYI) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new PBYI filing with AI-powered analysis.
What is the difference between 10-K, 10-Q, and 8-K SEC filings?
A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs, such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for PUMA BIOTECHNOLOGY, INC. (PBYI).
What is PBYI's SEC CIK number?
PUMA BIOTECHNOLOGY, INC. (PBYI)'s SEC CIK (Central Index Key) number is 1401667. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 1401667 to look up all PBYI filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.
Stay on top of PUMA BIOTECHNOLOGY, INC. SEC filings
Insider trading data, fund holdings, cross-signal detection, and AI-powered analysis for 96+ filings.